Management of Chronic Conditions
MM Category ID
2
MM Category
Promote Effective Prevention & Treatment of Chronic Disease
| CMS eCQM ID | Year | Type | Measure Name |
|---|---|---|---|
| CMS052v7 | 2019 | EP/EC | HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis |
| CMS065v8 | 2019 | EP/EC | Hypertension: Improvement in Blood Pressure |
| CMS122v7 | 2019 | EP/EC | Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%) |
| CMS122v8 | 2020 | EP/EC | Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%) |
| CMS123v7 | 2019 | EP/EC | Diabetes: Foot Exam |
| CMS131v7 | 2019 | EP/EC | Diabetes: Eye Exam |
| CMS131v8 | 2020 | EP/EC | Diabetes: Eye Exam |
| CMS132v7 | 2019 | EP/EC | Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures |
| CMS133v7 | 2019 | EP/EC | Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery |
| CMS133v8 | 2020 | EP/EC | Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery |
| CMS134v7 | 2019 | EP/EC | Diabetes: Medical Attention for Nephropathy |
| CMS134v8 | 2020 | EP/EC | Diabetes: Medical Attention for Nephropathy |
| CMS135v7 | 2019 | EP/EC | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
| CMS135v8 | 2020 | EP/EC | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
| CMS143v7 | 2019 | EP/EC | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
| CMS143v8 | 2020 | EP/EC | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
| CMS144v7 | 2019 | EP/EC | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
| CMS144v8 | 2020 | EP/EC | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
| CMS145v7 | 2019 | EP/EC | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |
| CMS145v8 | 2020 | EP/EC | Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |